Previous 10 | Next 10 |
2023-11-02 14:45:22 ET Summary Exelixis's Q3 earnings fell short of expectations, with lower-than-anticipated Earnings Per Share and total revenues. The company's pipeline includes innovative therapies and collaborations with partners to revolutionize cancer treatment. Despite...
2023-11-01 21:43:08 ET Exelixis (EXEL) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Mike Morrissey - President and Chief Executive Officer Chris S...
- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provi...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Exelixis Inc. (EXEL) is expected to report $0.12 for Q3 2023
2023-10-31 17:36:11 ET More on Exelixis Exelixis gains as Cabometyx patent trial ends Exelixis reports positive results for Cabometyx Exelixis started at Buy at Wainwright on targeted oncology pipeline For further details see: Exelixis Q3 2023 Earnings Pr...
2023-10-26 11:27:48 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...
2023-10-25 08:30:32 ET Palm Beach, FL – October 25, 2023 – FinancialNewsMedia.com News Commentary – The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is used to eithe...
2023-10-23 13:17:24 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...
2023-10-23 10:44:57 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...